Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01648348 : Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Histological confirmation of grade 3 or 4 glioma, including astrocytoma,
oligodendroglioma, and mixed gliomas, as determined by pre-registration central
pathology review (Phase I)

- Histological confirmation of glioblastoma multiforme (grade 4 astrocytoma) as
determined by pre-registration central pathology review; note: gliosarcomas and other
grade 4 astrocytoma variants (e.g., giant cell) are eligible (Phase II)

- Evidence of tumor progression by MRI or computed tomography (CT) scan following
radiation therapy or following the most recent anti-tumor therapy; note: patients who
have had surgical treatment at recurrence are eligible if they had a resection with
measurable or non-measurable residual disease on postoperative imaging or if there is
imaging evidence of disease progression as compared to the first postoperative scan

- Measurable or evaluable disease by gadolinium MRI or contrast CT scan; note: patients
who have had a gross total resection (GTR) are eligible on the basis of evaluable

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

- Absolute neutrophil count (ANC) >= 1,500/mm^3

- Platelet count >= 100,000/mm^3

- White blood cells (WBC) >= 3,000/mL

- Hemoglobin >= 10.0 g/dL; note: this level may be reached by transfusion

- Total bilirubin =< institutional upper limit of normal (ULN)

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<
2 x ULN

- Creatinine =< ULN

- Life expectancy >= 12 weeks

- Negative serum pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only

- Urine protein creatinine (UPC) ratio < 1; note: urine protein must be screened by
urine analysis for UPC ratio; for UPC ratio >= 1.0, 24-hour urine protein must be
obtained and the level should be < 1,000 mg for registration

- Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior
to registration

- Calculated glomerular filtration rate (GFR) must be >= 60 ml/min; GFR will be
calculated as needed per institutional guidelines

- Any number of prior chemotherapy regimens for recurrent disease (Phase I); =< 1
chemotherapy or other non-antiangiogenic regimen for recurrent disease (Phase II)

- Last dose of bevacizumab >= 2 weeks prior to registration (Phase I); note: for the
phase II study only, prior exposure to bevacizumab is not allowed

- Surgery >= 4 weeks prior to registration

- Completion of radiation therapy >= 12 weeks prior to registration and prior
chemotherapy >= 4 weeks prior to registration (>= 6 weeks from nitrosourea-containing

- Small molecular cell cycle inhibitors >= 2 weeks from registration

- Ability to provide informed written consent

- Ability to complete questionnaire(s) by themselves or with assistance

- Willing to return to enrolling institution for follow-up

- Willing to discontinue use of medications that inhibit platelet function >= 10 days
prior to registration; aspirin at doses greater than 325 mg/day must be discontinued
>= 10 days prior to registration and avoided through the study; note: nonsteroidal
anti-inflammatory drug (NSAID) medications are recommended in place of aspirin; if
NSAIDs or aspirin are used, histamine (H)-2 blockers and proton pump inhibitor (PPI)
medications are recommended

- Willing to provide mandatory blood and tissue samples for correlative research
purposes (Phase I and II)

Exclusion Criteria:

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception throughout the duration of the study and for at least 6 months
after treatment has ended

- Prior hypersensitivity to bevacizumab or toxicity requiring discontinuation of
bevacizumab (Phase I)

- Any prior exposure to any VEGF or VEGF inhibitor including, but not limited to,
bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept, or sorafenib
(Phase II)

- Prior hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies (Phase I and II)

- Prior hypersensitivity to triptan derivatives (Phase I and II)

- Other active malignancy =< 3 years prior to registration; exceptions: nonmelanotic
skin cancer or carcinoma-in-situ of the cervix; note: if there is a history of prior
malignancy, they must not be receiving other specific treatment (other than hormonal
therapy) for their cancer

- Uncontrolled infection

- Immunocompromised patients or patients known to be human immunodeficiency virus (HIV)
positive and currently receiving combination antiretroviral therapy; patients known
to be HIV positive, but without clinical evidence of an immunocompromised state, are
eligible for this trial

- Co-morbid systemic illnesses or other severe concurrent disease which, in the
judgment of the investigator, would make the patient inappropriate for entry into
this study or interfere significantly with the proper assessment of safety and
adverse events of the prescribed regimens

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, or psychiatric illness/social situations that would limit compliance with
study requirements

- History of hypertensive crisis or hypertensive encephalopathy

- Clinically significant cardiovascular disease defined as follows:

- Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] > 160
mm Hg and/or diastolic blood pressure [DBP] > 90 mm Hg despite antihypertensive

- History of cerebrovascular accident (CVA) within 6 months

- Myocardial infarction or unstable angina within 6 months

- New York Heart Association classification II, III, or IV cardiovascular disease

- Serious and inadequately controlled cardiac arrhythmia

- Significant vascular disease (i.e., aortic aneurysm, history of aortic

- Clinically significant peripheral vascular disease

- Evidence or history of bleeding diathesis (greater than normal risk of bleeding,
i.e., hereditary hemorrhagic telangiectasia type I or HHT-1) or coagulopathy in the
absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade 3
within 4 weeks prior to registration; note: patients with full-dose anticoagulants
are eligible provided the patient has been on a stable dose for at least 2 weeks of
low molecular weight heparin; therapeutic Coumadin and aspirin doses > 325 mg daily
are not allowed

- Receiving any other investigational agent that would be considered as a treatment for
the primary neoplasm

- Prior treatment with TRC105

- Serious or non-healing wound, active ulcer, or untreated bone fracture

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess =< 6 months prior to registration

- History of invasive procedures defined as follows:

- Major surgical procedure, open biopsy, or significant traumatic injury =< 28
days prior to registration

- Anticipation of need for major surgical procedures during the study

- Core biopsy =< 7 days prior to registration

- History of significant vascular disease (i.e., aortic aneurysm requiring surgical
repair, or recent peripheral arterial thrombosis) within 6 months prior to
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557